Yusen Logistics to Acquire Walden Health

Walden Group, a European logistics provider active in temperature-controlled logistics and last-mile delivery solutions for the healthcare and pharmaceutical sectors as well as express delivery, today announced it has entered into exclusive negotiations in relation to the potential sale of its healthcare activities to Yusen Logistics Group, a Japan-based global logistics company fully owned by NYK Line, the largest Japanese shipping company.

Building on a leading position in Europe, the potential transaction would enable Walden Health to accelerate its growth, expand its international reach, and enhance its service by benefitting from Yusen Logistics Group’s global network and integrated logistics capabilities.

Shared Vision for Healthcare Logistics

Founded in 1951, Walden has since been at focused on pharmaceutical and healthcare market trends, with an offering of a wide range of value-added services tailored to clients’ needs. Walden has grown from a French to a pan-European operator through a successful combination of organic growth and acquisitions, having notably acquired Movianto from Owens and Minor in 2020. As the healthcare logistics market becomes increasingly global, the proposed transaction would ensure that Walden Health is best positioned as it enters its next phase of growth, involving:

• Expansion of its footprint beyond Europe
• Building on Yusen Logistics Group’s global infrastructure and digital capabilities to enhance service quality and resilience
• Continued investment in sustainable, compliant, and temperature-controlled logistics solutions

“Today’s announcement is a significant step in our journey to become a leading healthcare logistics player and we look forward to welcoming Walden Health into our group. We have been expanding healthcare logistics for the past years by enhancing our capability worldwide to provide customers with various logistics services. We believe combination between Walden Health’s high professionalism with longstanding reputation and our global network can make our healthcare logistics service truly unique” said Hiroki Harada, CEO and Chairman of the Board of Yusen Logistics Group.

“We are proud of the journey Walden has taken to become a trusted partner in healthcare logistics across Europe,” said Stephane Baudry, Chairman of Walden Group and grandson of Marcel Baudry, the founder of Walden, formerly known as CSP. “Thanks to Yusen Logistics Group, Walden Health will develop into a truly global player, capable of offering end-to-end services to clients, building on a strong innovative DNA focused on improving patient care with an unwavering commitment to quality. I am delighted to see the strong cultural and strategic fit of the two organizations and truly believe that Walden Health is set for continued success”

Continuity and Growth

While the healthcare division plans to embark on this new journey, Walden Group will continue to invest in its mobility division, including Ciblex and Relais Colis, where exciting opportunities lie ahead in express transport and last-mile delivery.

similar news

TMS Investment Aims to Push Healthcare Logistics for Yusen

 

Private Jets Transporting Vital Medical Equipment

Think of a private jet and you might imagine celebrities, millionaires and high-flying business owners summoning a first-class flight to transport them to a luxury location. Yet, these planes are also an essential tool in healthcare logistics, helping transport vital equipment around the globe, and often enabling medicine, blood and organs to reach their destination quicker than any commercial aircraft could, writes Vickie Clark, MD of V Jets.

Life and death stakes

Across the world, 85 million units of blood are transfused every year – with many requiring a co-ordinated logistics effort to reach the patient in a timely manner. Individuals in a critical condition need their blood transfusion to begin within just a few hours, to prevent life-threatening complications.

In the case of organ donation, more sensitive organs such as the heart and lungs must be transplanted within four to six hours, otherwise they risk no longer being viable. Even more resilient organs such as the liver and kidneys require transplantation within 12 hours and 24 to 36 hours respectively to maximise the chance of successful surgery (Donor Alliance).

Even where a commercial airline route could feasibly be used to transport the donor organ, there are limitations involved with this choice: for example, in America the organ must arrive at the airport between an hour and two hours before flight departure, and the cargo office at the destination airport must be open when the flight arrives to ensure the organ can be collected by a courier. The organs are also stored within the cargo hold alongside the checked-in baggage of the flight’s passengers, presenting a potential risk when it comes to safe transportation. In fact, the US Organ Procurement and Transplantation Network cites 2.5% of unused organs can’t be donated due to transport issues.

Luxury lifesavers

Why are private jets preferable? Research suggests private jets may be up to five times quicker end-to-end than commercial airlines or land ambulances when it comes to transporting organs, blood donations and other medical equipment.

This is due to a combination of reasons, not least the ability to use smaller airports, more flexible routes, and faster flight speeds. A jet can be ready to go in as little as two hours after a request has been submitted – and can often land at an airport closer to the destination medical centre, or even a field hospital or rural community. This is especially crucial to allow those in remote areas access to the same kind of medical intervention as their urban counterparts, whose medical facilities are generally nearer a large, commercial airport.

If you’re racing against the clock, there is no room for delays – in those situations, private planes aren’t just moving cargo, they’re delivering hope. When it comes to the use of private jets to transport medical supplies, it’s important to remember the reality – that at least one life can be normally be saved but only if the transportation is swift.

There are so many examples of such life-saving missions, like the 7-year-old boy who needed an emergency transfusion after a serious accident in the Caribbean. His rare blood type was not available locally and there were no commercial flights due to land on the island for the next 48 hours – so a private jet delivered the much-needed blood from Miami in less than five hours.

Sometimes, it’s not an isolated incident but a full-scale crisis which requires private planes to be drafted in to support medics on the ground. In Sudan in 2023, commercial airlines suspended services due to the conflict there, but aid organisations were desperate for medical supplies, utilising private jets to ensure they arrived as quickly as possible.

And in West Africa, when there was an Ebola flare-up, a private jet flew in hazmat suits, mobile isolation units and specialised antivirals for WHO doctors. The supplies arrived in ten hours, compared to the three days it would have taken to transport them commercially. When roads are destroyed, airports are shut, and time is running out, a private jet can still make it through, giving hope to those previously battling against seemingly unbeatable odds. This is the side of private aviation that people don’t see – flying stem cells, vaccines, and hearts to patients in need.

Whether due to natural disaster, political unrest, a sudden disease outbreak, or a life hanging in the balance due to illness or accident, time and efficiency is of the essence – and that’s when the private aviation sector proves its about more than just A-listers and corporate giants: it’s capable of saving lives.

similar news

GEFCO Flies Emergency Medical Supplies from China to Central Europe

 

NHS Supply Chain Awards LSP Contract

NHS Supply Chain has awarded the contract for the management of its logistics services to GXO. The company will be taking over the contract for storing and delivering healthcare products to the NHS on behalf of NHS Supply Chain from October this year, when the current outsourced Logistics Services Provider’s contract expires. The contract is for an initial period of seven years, with a possible extension of up to 36 months.

NHS Supply Chain chief executive officer, Andrew New said: “We’re pleased to announce GXO as the new service provider for our logistics services. Running our eight distribution centres across England and keeping our significant fleet of more than 300 delivery vehicles on the road is a key part of what we do to supply the NHS with more than 35 million healthcare products every year. We’re an important part of the healthcare system, ensuring the NHS can put patients first. As well as running our normal logistics services, looking forward to the future, we will be developing our logistics services with GXO to best meet the growing needs of the NHS.”

“We are extremely proud to have been selected to serve the NHS as its new logistics partner,” said Gavin Williams, managing director, GXO UK & Ireland. “Combining our sector experience with the technology expertise that supports many of the UK’s leading businesses will optimise the NHS’s logistics services for healthcare providers and taxpayers. We are committed to an excellent quality of service to hospitals and patients at home, increasing productivity and supporting our NHS so that it can focus on patients, its ultimate priority.”

GXO will be contracting with Polar Speed to provide NHS Supply Chain’s Home Delivery Services. There will be a transition period over the next few months to ensure a smooth handover of sites and teams from the current logistics provider to GXO and Polar Speed, ensuring the NHS continues to receive the service it needs.

The role is to source, deliver and supply healthcare products, services and food for NHS trusts and healthcare organisations across England and Wales. Supply Chain Coordination Ltd (SCCL) is the company at the heart of NHS Supply Chain. It provides oversight and operational management for NHS Supply Chain and its service providers. SCCL is the legal entity through which NHS Supply Chain undertakes its procurement services and transacts with customers and suppliers. Whilst its shares are owned by NHS England, SCCL is a separate organisation.

similar news

NHS Supply Chain: Bids for Logistics Services Provider

 

Life Sciences and Healthcare Logistics Enhanced

DHL Group has announced a strategic investment of €2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector. This investment supports the Group’s ‘Strategy 2030’ and reinforces DHL’s commitment to helping healthcare customers grow, innovate, and serve patients more effectively worldwide. With 50% of the investment allocated to the Americas, 25% to Asia Pacific, and 25% to the EMEA region, DHL is expanding its global footprint to deliver integrated, faster, more reliable, and patient-centric logistics solutions wherever healthcare companies operate.

The investment will focus on enhancing high-quality infrastructure and technology across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery – creating even more resilient, scalable, and responsive supply chains for customers. A significant part of the investment will be allocated to establishing new cross-divisional GPD-certified Pharma Hubs for multi-temperature shipments lanes, expanding cold chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging solutions to ensure sustainable delivery.

As the demand grows in critical areas such as clinical trials, biopharma, and cell and gene therapies, DHL is also investing in high-quality, specialized cooling infrastructure to accommodate low and ultralow temperature ranges. Additionally, the Group will implement cutting-edge IT systems that provide end-to-end visibility, ensuring product integrity, regulatory compliance, and confidence for healthcare providers and their patients.

With its new sector brand DHL Health Logistics, the Group consolidates its life sciences and healthcare expertise under one unified umbrella. This creates a seamless, end-to-end experience for customers, simplifying the management of complex, cross-border supply chains with confidence, agility and high quality service. The approach is designed to meet the needs of pharmaceutical, biopharma, and medical customers who require agile, connected logistics solutions that go beyond traditional service lines.

“Similar to DHL Group’s purpose of ‘Connecting people, improving lives’, our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create – ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”

DHL Group has long been a partner in life sciences and healthcare logistics, contributing over EUR 5 billion in global revenue in 2024. With an additional EUR 5 billion in projected incremental revenue by 2030, DHL Group is scaling its operations to match the fast-evolving needs of the industry and its end-users – healthcare professionals and patients alike.

Through this strategic investment, DHL Group is not only reinforcing its commitment to the life science and healthcare sector but also demonstrating a profound dedication to patient care by ensuring the efficient and reliable delivery of essential pharmaceutical products, clinical trials and cell and gene therapies. This approach positions DHL Group at the forefront of the industry, fully equipped to tackle challenges and seize opportunities in a rapidly transforming market.

Currently, DHL Group operates nearly 600 sites, hubs, and warehouses across close to 130 countries dedicated to life sciences and healthcare logistics, encompassing a total of more than 2,5 million square meters of temperature-controlled warehouse space. Building on this extensive network, our customers benefit from a comprehensive portfolio of fully integrated solutions. In addition to infrastructure investments, DHL Group has recently acquired CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies, to further strengthen its capabilities in this segment and expand the potential of its Pharma Specialized Network as part of the overall investment strategy.

similar news

Heathrow Life Sciences and Healthcare Facility Opened by GEFCO

 

Subscribe

Get notified about New Episodes of our Podcast, New Magazine Issues and stay updated with our Weekly Newsletter.